Business Wire

World FZO Brings Its 12 th World Congress to Panama in 2026

31.7.2025 09:00:00 CEST | Business Wire | Press Release

Share

The World Free Zones Organization announced the signing of a Memorandum of Understanding with the government of Panama to host the 12th annual World FZO’s World Congress in the country’s capital, Panama City, in July 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731827900/en/

H.E. Dr. Al Zarooni Signing the MoU with the Minister of Commerce and Industries in Panama (Photo: AETOSWire)

The MoU was signed by His Excellency Dr. Mohammed AlZarooni, Chairman of the World FZO, and His Excellency Julio Moltó, Minister of Commerce and Industries at the Government of the Republic of Panama, in the presence of senior officials from both sides.

The announcement was made during an official visit led by Dr. AlZarooni to Panama City, where he met with His Excellency José Raúl Molino Quintero, President of the Republic of Panama. On the sidelines of the visit, the delegation toured key sites in Panama, including the Colón Free Trade Zone, PANAPARK Free Zone, and the Panama Canal.

Under the MoU, both parties will collaborate to deliver a high-caliber edition of the World FZO World Congress, that convenes decision-makers, freezone leaders, and investors from more than 100 countries, in addition to attracting major economic institutions from around the world. The event is expected to strengthen Panama’s global standing as a hub for trade and logistics and enhance its visibility on the international investment map.

H.E. Dr. AlZarooni,said:“World FZO is committed to forging strategic partnerships that enhance the role of freezones as drivers of global growth, based on the importance of developing platforms for international dialogue and cooperation to keep up with the major shifts taking place in the global economy. Our cooperation with the government of Panama represents a key milestone in our efforts to outreach to Latin American markets and strengthen cooperation with governments and economic institutions in this vital region.”

H.E. Julio Moltó,said: “Hosting the Congress represents a strategic step that highlights Panama's position as a global investment gateway and opens new prospects for regional cooperation, technology, and investment. We are committed to providing all necessary elements to ensure the success of this crucial event, in cooperation with the Organization. We value our partnership with World FZO and look forward to leveraging its extensive experience in the development and administration of freezones internationally, which will enhance the competitiveness of Panama’s business environment and open our economy to global markets.”

This announcement comes as preparations continue for the 11th World FZO Congress, set to take place in Hainan province, China, from 10–12 October 2025, held with the Hainan International Economic Development Bureau. The back-to-back hosting of the Congress in both China and then Panama reflects the growing momentum of the World FZO on the international stage.

The World FZO World Congress is the world's premier gathering of freezone leaders, government officials, investors, and trade experts. It gathers more than 1,500 delegates from over 100 countries, bringing together a select group of decision-makers, and high-level representatives from global industry, trade, and investment sectors.

Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731827900/en/

Contacts

World-FZO Media
Mazen Dirany
meldirany@diez.ae

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye